Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects with Severe Refractory Asthma

Next Previous
X
Search
Trial Profile

MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects with Severe Refractory Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary) ; Prednisolone; Prednisone
  • Indications Asthma
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms SIRIUS
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 16 Mar 2020 Results (n=1189) of post-hoc pooled analysis of four studies ( DREAM, MENSA, SIRIUS, and MUSCA ) assessing impact of mepolizumab on clinically significant exacerbations and health-related quality of life (HRQoL) in patients with severe eosinophilic asthma and upper respiratory comorbidities, published at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 01 May 2019 Results assessing disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of >/=150-300cells/muL using data from DREAM, MENSA, SIRIUS and MUSCA studies, published in the Respiratory Medicine
    • 19 Sep 2018 Results of a post-hoc analysis from NCT01000506, NCT01691521, NCT02281318, NCT01691508 and NCT02377427 studies, presented at the 28th Annual Congress of the European Respiratory Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top